UAE Pharmaceutical Distribution Reform: What It Means for Market Access, Supply Chains, and Drug Security

The new pharmaceutical distribution reform in the UAE aim to strengthen drug security, reduce single-agent risks, and reshape market access.

Find Business Support

Our Business Advisory service helps companies navigate Asia’s complex business landscape from initial market entry to ongo...

The UAE pharmaceutical industry is entering a new phase of regulatory and commercial restructuring. As demand for medicines grows, supply chains become more complex, and the country positions itself as a regional life sciences hub, the government is moving to reduce concentration risk in pharmaceutical distribution.

On February 24, 2026, the Emirates Drug Establishment announced a new mechanism requiring pharmaceutical companies marketing medical products in the UAE to appoint more than one authorized local agent for each product. The reform, implemented under Federal Decree-Law No. 38 of 2024 Governing Medical Products, Pharmacists and Pharmaceutical Establishments, is designed to end reliance on single-agent distribution arrangements and strengthen pharmaceutical security across the country.

For the pharmaceutical industry, the measure changes how manufacturers, distributors, logistics providers, hospitals, and pharmacies will need to think about market access, supply continuity, inventory management, and partner selection in the UAE.

UAE pharmaceutical market and supply chain overview

The UAE pharmaceutical market is expanding steadily, supported by population growth, medical tourism, higher healthcare spending, chronic disease management, and demand for innovative therapies. The market is estimated to have generated revenue of US$5.0 billion in 2025 and is expected to reach US$8.0 billion by 2033, growing at a compound annual growth rate of 6.1 percent from 2026 to 2033. Biologics and biosimilars are considered the fastest-growing molecule segment over the forecast period.

Other key drivers of for the sector expansions are:

• Chronic disease prevalence;
• Government healthcare investment;
• Medical tourism;
• Expanding local manufacturing; and
• Regulatory reform.

This growth is increasing the strategic importance of distribution. Pharmaceuticals require regulated storage, reliable cold-chain logistics, batch traceability, pharmacovigilance, controlled pricing, and continuous availability in public and private healthcare channels. The more the market shifts toward biologics, specialty drugs, oncology treatments, vaccines, and other high-value therapies, the more important resilient distribution becomes.

 Why the single-agent model created industry risk

Historically, pharmaceutical distribution in the UAE often relied on a single authorised local agent for a given product. This model offered manufacturers a clear commercial counterpart and gave local agents strong market positions. However, it also created concentration risk.

If one agent controlled access to a product, any disruption affecting that agent could affect the availability of the medicine across the market. Risks could include inventory shortages, warehousing constraints, customs delays, financial disputes, compliance issues, cold-chain failures, or limited geographic coverage.

The new mechanism directly addresses this vulnerability by requiring more than one authorised agent for each medical product. According to the EDE, the objective is to strengthen pharmaceutical security, ensure sustainable product availability, enhance supply chain flexibility, and improve national readiness during emergencies.

For businesses, the message is clear: distribution resilience is becoming a regulatory priority, not only an operational best practice.

Commercial implications for pharmaceutical manufacturers

For international pharmaceutical companies, the reform may require a reassessment of UAE market access strategies. Manufacturers will need to review existing agency agreements, identify exclusivity provisions, and determine how to appoint additional authorised agents without weakening compliance, pricing discipline, or brand control.

A multi-agent model can provide several commercial advantages. It reduces dependence on a single distributor, improves the ability to respond to sudden demand changes, and allows manufacturers to segment partners by geography, healthcare channel, therapeutic area, or logistics capability. For example, one agent may be stronger in hospital tenders, while another may have better retail pharmacy coverage or cold-chain infrastructure.

At the same time, the model introduces coordination challenges. Manufacturers will need clearer rules on stock allocation, tender participation, product information, adverse event reporting, pricing, and customer relationship management. Without strong oversight, multiple-agent distribution could lead to fragmented execution.

New competitive pressure for local distributors

For UAE-based pharmaceutical distributors, the reform changes the basis of competition. Companies that previously benefited from exclusive agency arrangements may face pressure as manufacturers appoint additional partners. This could reduce the commercial value of exclusivity and increase competition on service quality, coverage, logistics, and compliance.

However, the reform also creates new opportunities. Distributors with strong infrastructure may be able to secure authorised-agent roles for products previously controlled by competitors. This is particularly relevant for companies with advanced warehousing, temperature-controlled logistics, hospital networks, tendering expertise, digital inventory systems, and regulatory compliance teams.

The UAE’s new medical products framework also reflects a broader move toward a more specialised pharmaceutical ecosystem. Federal Decree-Law No. 38 of 2024 covers medical products, pharmacists, pharmaceutical establishments, warehouses, medical stores, factories, laboratories, research and development contractors, and other sector participants. ([Ministry of Health and Prevention – UAE][4])

This suggests that the UAE is not only reforming distribution rules, but also strengthening the institutional framework around the entire pharmaceutical value chain.

Supply chain resilience becomes a business differentiator

The reform should also be read in the context of regional healthcare resilience. The Middle East and Africa pharmaceutical market generated revenue of USD 63.4 billion in 2025 and is forecast to reach US$93.4 billion by 2033, with the UAE expected to be the fastest-growing country market in the region, according to Grand View Research.

As the UAE grows as a regional pharmaceutical trade, healthcare, and logistics hub, supply chain reliability becomes part of its investment proposition. Pharmaceutical companies considering the UAE as a regional base will look not only at licensing and market size, but also at whether the country can provide predictable distribution, regulatory clarity, and emergency supply continuity.

The multi-agent mechanism may therefore support the UAE’s wider ambition to become a more competitive life sciences hub. A more diversified distribution structure can reduce bottlenecks, improve medicine availability, and increase investor confidence in the reliability of the domestic market.

What businesses should do next

Pharmaceutical companies, distributors, and healthcare operators should treat the reform as an opportunity to reassess their UAE operating models.

• Pharmaceutical manufacturers: Review agency agreements, appoint qualified additional agents, and strengthen partner governance;
• Local distributors: Invest in logistics, compliance, cold-chain capacity, and digital inventory visibility
• Hospitals and pharmacies: Review supplier diversification and medicine availability planning;
• Logistics providers: Position cold-chain and regulated warehousing as core value propositions; and
• Investors: Assess opportunities in distribution, manufacturing, warehousing, and specialty pharma services.

Companies should also monitor future implementing guidance from the EDE, particularly on timelines, registration procedures, agent responsibilities, product categories, and enforcement expectations.

Outlook

The UAE’s pharmaceutical distribution reform reflects a broader industry shift: medicine availability is now being treated as a matter of economic competitiveness, healthcare resilience, and national security.

Find Business Support

How we can help companies navigate the environment and cleantech industry in Asia and the Middle East

For manufacturers, the new mechanism will require more sophisticated market access and partner management. For distributors, it will increase competition but reward operational capability. For logistics providers, it will strengthen demand for regulated warehousing, cold-chain systems, and inventory management. For healthcare providers and patients, the intended outcome is more reliable access to essential and specialised medicines.

As the UAE pharmaceutical market continues to grow, the move away from single-agent distribution could become an important pillar of the country’s wider life sciences strategy, supporting a more resilient, competitive, and investment-ready pharmaceutical ecosystem.

• Previous Article Sustainable Aviation Fuels In the Middle East Aviation Sector: Insights and Opportunities
• Next Article